Ninlaro (ixazomib) / Takeda - LARVOL DELTA

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: National Cancer Institute (NCI) | Phase classification: P1b ➔ P1

Phase classification • Hematological Malignancies • Multiple Myeloma • Oncology

Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma. (PubMed, Future Sci OA) - "This study assesses the cost-effectiveness of carfilzomib plus lenalidomide and dexamethasone (KRd) versus ixazomib plus lenalidomide and dexamethasone for relapsed and refractory multiple myeloma (RRMM) in China. At a $40,023.27 willingness-to-pay (WTP) threshold, the carfilzomib combination has a 100% probability of being cost-effective. The study shows that, based on evidence from indirect comparisons, KRd is a cost-effective treatment option for RRMM patients in China."

HEOR • Journal • Hematological Malignancies • Multiple Myeloma • Oncology

THE IRD REGIMEN CONTINUED AFTER EFFECTIVE INDUCTION WITH DRD FOR TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: A MULTI-CENTER PROSPECTIVE STUDY IN CHINA (EHA 2025) - P4 | "Background: The continuous treatment regimen of DRd (daratumumab/lenalidomide/dexamethasone) has been proven to significantly improve the prognosis of newly diagnosed multiple myeloma(NDMM)patients...Aims: The primary research objective is to observe the 2-year progression-free survival (PFS) in transplant-ineligible patients with NDMM after sequential IRd(ixazomib/lenalidomide/dexamethasone)regimen treatment following DRd regimen induction therapy... In conclusion, outcomes of the study indicate that sequential IRd regimen treatment following DRd regimen induction therapy in transplant-ineligible patients with NDMM can further deepen the depth of remission and safety data suggest IRd is generally well tolerated."

Clinical • Infectious Disease • Multiple Myeloma • Pain • Transplantation

CLINICAL OUTCOMES OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA OVERALL AND AMONG LENALIDOMIDE-REFRACTORY PATIENTS IN EAST ASIA: A TARGETED LITERATURE REVIEW (EHA 2025) - "Treatment regimens: thalidomide + dexamethasone (DEX; South Korea); ixazomib (IXA) + LEN + DEX (Japan); daratumumab + DEX + cyclophosphamide + etoposide + cisplatin (CN); IXA + clarithromycin + LEN + DEX (CN).Among LEN-refractory pts in EA: median PFS 5.5-11.9mo, median OS 9.2-12mo, ORR 20-65% (DOR not reported). In CN, a retrospective review of 17 LEN+bortezomib-refractory pts reported: median PFS 8mo, median OS 12mo, ORR 65%; another study with 42.9% (12/28) of LEN-refractory pts reported: median PFS 11.7mo, ORR 50% (OS not reported)... RRMM clinical outcomes are poor in EA under the existing treatments available, with studies generally reporting OS <2yrs overall and <1yr in LEN-refractory pts. Data across EA were highly variable, likely due to differences in line of treatment at time of study, differing efficacy/accessibility of RRMM treatment options, and small study sizes, especially in LEN-refractory pts. LEN-refractory pt data were scarce and inconsistently..."

Clinical • Clinical data • Review • Hematological Malignancies • Multiple Myeloma • Oncology

COMPARISON OF EFFICACY AND SAFETY BETWEEN IXAZOMIB BASED AND LENALIDOMIDE BASED INDUCTION IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (EHA 2025) - "Aims: To compare the efficacy and safety of Ixazomib/cyclophosphamide/dexamethasone (ICd) and lenalidomide/cyclophosphamide/dexamethasone (RCd) treatment in older patients with TI-NDMM. The ICd regimen showed a tendency towards improved ORR, particularly in high-risk cytogenetic patients, compared to RCd. Both ICd and RCd regimens demonstrated less dose reduction and treatment discontinuation, suggesting their tolerability and feasibility for older individuals with TI-NDMM."

Clinical • Anemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases

EFFICACY AND SAFETY OF CARFILZOMIB-BASED REGIMENS IN MULTIPLE MYELOMA: A RETROSPECTIVE STUDY (EHA 2025) - "Statistical analyses included progression-free survival (PFS), overall survival (OS), and subgroup analyses based on age, renal function, cytogenetic risk, and prior treatment lines.A total of 44 patients were included and received carfilzomib-based regimens, including DKD (Daratumumab, Carfilzomib, Dexamethasone), KPD (Carfilzomib, Pomalidomide, Dexamethasone), KD (Carfilzomib, Dexamethasone), KRD (Carfilzomib, Lenalidomide, Dexamethasone), XKD (Selinexor, Carfilzomib, Dexamethasone), DKPD (Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone), DKRD (Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone), and KRD-PACE (Carfilzomib, Lenalidomide, Dexamethasone, Cisplatin, Doxorubicin, Cyclophosphamide, Etoposide)...The distribution of cytogenetic abnormalities and other baseline characteristics were as follows: Del17p/TP53, t(4; 14),t(14; 16),t(14; 20), del(1p32) and 1q gain/amp 25%, extramedullary disease 18.9%, PI (bortezomib/Ixazomib)-refractory 59.5%,..."

Retrospective data • Anemia • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Multiple Myeloma • Neutropenia • Thrombocytopenia • TP53

IXAZOMIB-BASED MAINTENANCE THERAPY IN REAL-WORLD PRACTICE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS (EHA 2025) - "Now we further compared the outcomes of ixazomib alone (Group I) and ixazomib combined with lenalidomide (Group IR) as maintenance therapy. This multicenter, retrospective, real-world study evaluated the efficacy of I and IR maintenance therapies in NDMM. The findings showed no significant differences in long-term outcomes, consistent with previous reports. Notably, additional analyses suggested that the biweekly dosing regimen of ixazomib also provides effective treatment, offering potential insights for future clinical practice."

Clinical • Real-world • Real-world evidence • Anemia • Multiple Myeloma • Neutropenia • Pain • Thrombocytopenia

MAINTENANCE THERAPY FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANTATION BY IXAZOMIB,LENALIDOMIDE,OR IXAZOMIB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH MULTIPLE MYELOMA: A MULTI-CENTERED STUDY IN CHINA (EHA 2025) - P4 | "In our multicentered prospective real-world study, maintenance regimens either with ixazomib, lenalidomide or combination in MM patients receiving ASCT all improves post-transplant response.More high-risk patients were assigned to ixazomib or combined regimen. Although dual drug maintenance with ixazomib and lenalidomide dose not maximize efficacy or survival outcome compare to single agent, But in 1q gains subpopulations, IR group represent relatively longer PFS.Analysis of subgroups needs to be conducted in larger population and extend the follow-up time to confirm."

Clinical • Combination therapy • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Multiple Myeloma • Oncology • Pain • Transplantation

REAL-WORLD DURATION OF TREATMENT IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) RECEIVING THE PROTEASOME INHIBITOR IXAZOMIB THROUGH THE GLOBAL IXAZOMIB EXPANDED ACCESS PROGRAM (EAP) (EHA 2025) - "Background: Following the TOURMALINE-MM1 trial, ixazomib was approved by the FDA in 2015 and by the EMA in 2016 in combination with lenalidomide and dexamethasone (IRd) as an all-oral regimen for pts with MM who had received ≥1 prior line of therapy (LoT). Among 2,684 pts treated with ixazomib as part of this EAP, median TTD/DOT was 8 months in the overall population. Similar median TTD/DOT findings were seen across age and sex subgroups but were varied by geographic region. In a diverse population of likely heavily pretreated pts who had exhausted standard therapies available in routine care settings at that time, the ixazomib TTD/DOT observed was generally consistent with DOTs observed for heavily pretreated pts in other real-world studies with ixazomib (Leleu et al, Future Oncol 2024)."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology

IMPACT OF MASS SPECTROMETRY ON THE EVALUATION OF MAINTENANCE TREATMENT IN PATIENTS WITH MYELOMA ENROLLED IN THE GEM2014MAIN TRIAL: INSIGHTS INTO TREATMENT RESPONSE AND DISEASE PROGRESSION (EHA 2025) - "Patients were randomized to receive lenalidomide and dexamethasone (Rd; lenalidomide 15 mg/day on days 1-21 plus dexamethasone 20 mg/day on days 1-4 and 9-12 in 4-week cycles) or Rd plus ixazomib (4 mg on days 1, 8, and 15). Our findings demonstrate that MS is a valuable tool for monitoring residual disease and detecting early relapse in myeloma patients. MS provides real-time insights into disease dynamics, potentially allowing for personalized treatment strategies to improve patient outcomes. Therefore, MS could be incorporated into myeloma management and used to determine the optimal duration of maintenance therapy."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

A REAL-WORLD STUDY OF LENALIDOMIDE REFRACTORY MULTIPLE MYELOMA PATIENTS IN FINLAND: TREATMENT AND OUTCOMES (EHA 2025) - "As part of these treatment lines 97 (96.0%) patients had received bortezomib, 10 (9.9%) ixazomib and 22 (21.8%) carfilzomib. All 101 (100%) had received lenalidomide, while 12 (11.9%) pomalidomide and 11 (10.9%) thalidomide. Daratumumab was administered to 18 (17.8%) patients.The index-treatment consisted of pomalidomide and dexamethasone combined with either cyclophosphamide (26%), daratumumab (21%), karfilzomib (8%), isatuximab (7%) or bortezomib (5%). Additionally, 10% were treated with carfilzomib combined with daratumumab and dexamethasone and 23% with another triplet or quadruplet regimen... This retrospective study underscores the limited efficacy of modern triplet and quadruplet therapies in a lenalidomide refractory, real-world localized MM population treated in the Finnish health care system. The short TTNT and OS highlight the ongoing challenges in achieving substantial disease control and improving survival outcomes for these patients."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology

IN-CLASS TRANSITION (ICT) FROM PARENTERAL BORTEZOMIB (V) TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF US MM-6 BY RACE/ETHNICITY, RENAL FUNCTION, AND AREA INCOME (EHA 2025) - P4 | "The study demonstrated that iCT from parenteral V‑based induction to all-oral ixazomib/lenalidomide/dexamethasone (IRd) allows for prolonged PI-based therapy (Rifkin, BCJ 2023). This analysis of US MM-6 indicates the effectiveness and tolerability of iCT from V‑based induction to oral IRd in pt subgroups that are often underrepresented in clinical trials. iCT from V‑based induction to IRd provides an alternate and convenient approach for pts (including minorities) to achieve long-term PI treatment. Further research in key subgroups of pts with NDMM, while accounting for treatment cohort imbalances, is needed to support these findings."

Hematological Malignancies • Multiple Myeloma • Oncology • Renal Disease

IMPACT OF SALVAGE THERAPY ON OUTCOMES OF PATIENTS WITH FUNCTIONAL HIGH RISK MULTIPLE MYELOMA FROM THE HONEUR FEDERATED DATA NETWORK (EHA 2025) - "Most patients received salvage therapy with Rd: 30% and 22% (R=Lenalidomide, d=Dexamethasone) for FHR and controls respectively, distribution of 2L regimens is shown in figure. Comparing pts characteristics according to 2L salvage shows that pts treated with Rd/IRd, (I=Ixazomib) were older: pts ≥75 years were 36/42% compared to KRd 12% and DRd 21% (p<0.01) (K=Carfilzomib, D=Daratumumab)... In this real-world registry, favorable OS and TTNT were demonstrated among patients with FHR who were salvaged with DRd compared to alternative standard of care salvage regimens, yet DRd outcomes of FHR pts remained inferior to pts without FHR. Potent upfront and salvage regimens are warranted to improve outcomes of this poor prognosis group."

Clinical • Hematological Disorders • Hematological Malignancies • Monoclonal Gammopathy • Multiple Myeloma • Oncology

THE EFFICACY AND SAFETY OF DARATUMUMAB-BASED REGIMENS IN THE INITIAL TREATMENT OF AMYLOID LIGHT-CHAIN AMYLOIDOSIS (EHA 2025) - "Daratumumab combination therapy regimens included the VCD (bortezomib, cyclophosphamide, and dexamethasone), VD (bortezomib and dexamethasone), ID (ixazomib and dexamethasone), RD(lenalidomide and dexamethasone), PD (pomalidomide and dexamethasone), MP (melphalan and dexamethasone), and MTD regimens (melphalan, thalidomide, and dexamethasone).Patients underwent a median of 7 treatment cycles (range: 2-12), with a hematologic overall response rate (ORR), complete response (CR) rate, median time to response (TTR), and median time to maximal response (TMR) of ≥95.4%, 47.7%, 40 days, and 90 days, respectively... In the present study, Daratumumab-based regimens rapidly induce high-level hematologic responses in , significantly surpassing conventional chemotherapy regimens in cardiac and renal response rates and response speed. The treatment was well-tolerated by patients, and there were no unintended adverse reactions observed outside of clinical trials and no cases of..."

Clinical • Amyloidosis

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH TWO TO FOUR LINES OF TREATMENT IN THE PREAMBLE REGISTRY (EHA 2025) - P | "Patients whose 2L therapy began before the daratumumab (DARA), lenalidomide (LEN), and dexamethasone (DEX) (DRd) approval date (Nov 21, 2016 in the United States; Nov 22, 2017 in Canada; May 18, 2017 in Europe) were excluded...Prior to initiation of 2L, 3L, and 4L therapy, 70%, 83%, and 96% of patients had been exposed to LEN, 94%, 94%, and 98% to bortezomib (BORT), and 6%, 36%, and 64% to an anti-CD38 monoclonal antibody (mAb), respectively...The most common treatment regimens (± DEX) at 2L were BORT + DARA (13%), DARA + LEN (12%), and LEN (11%); at 3L, ixazomib + LEN (9%), DARA + pomalidomide (POM) (7%), and BORT + DARA (7%); and at 4L, elotuzumab + POM (8%), POM (7%), and DARA + POM (4%)... Despite the availability of numerous options for the treatment of RRMM, outcomes remain poor for patients, even in early-line RRMM. Our findings highlight the impact of prior therapies on treatment outcomes in RRMM, and worsening survival in later LOTs, underscoring the..."

Clinical • Clinical data • HEOR • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology

THE IMMUNOMODULATORY EFFECTS OF DARATUMUMAB-BASED THERAPY ON FUNCTIONAL HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA (FHRMM) PATIENTS ENROLLED IN THE MYDRUG OBSERVATIONAL TRIAL (EHA 2025) - P1/2 | "Functional high risk relapse/refractory multiple myeloma (fHRMM) patients with no discernible activating mutations and who had received 1-3 prior therapies (exposed to at least one proteasome inhibitor and an IMiD) were given a combination of daratumumab (D), ixazomib (I), pomalidomide (P) and dexamethasone (d) (D-IPd) quadruplet therapy. These data indicate that paired single cell RNA and TCR sequencing of BM T cells from RRMM patients receiving D-IPd quadruplet therapy revealed a selective expansion of clonotypic CD8+ T cells. These results support further explorations of rational combinations of targeted and immune therapies for greater efficacy in this disease."

Clinical • Immunomodulating • IO biomarker • Observational data • Hematological Malignancies • Multiple Myeloma • Oncology • BRAF • CD8 • CDKN2C • FGFR3 • IDH2 • KRAS • NRAS • SDC1

SAFETY AND EFFICACY OF IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE AS 2ND OR 3RD LINE TREATMENT FOR TRIPLE EXPOSED MULTIPLE MYELOMA PATIENTS: A PHASE II MULTI-CENTER TRIAL (IPOD-790) (EHA 2025) - P2 | "A phase 2, investigator initiated, open-label, single-arm, prospective, multicenter study evaluating IPd regimen as 2nd or 3rd line treatment for pts with RRMM who progressed after receiving bortezomib (BTZ), lenalidomide (LEN) and daratumumab (DARA). All oral IPd regimen for TCE RRMM pts showed high response rates with durable remissions and manageable safety profile, including in elderly and frail pts."

Clinical • P2 data • Anemia • Bone Marrow Transplantation • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia

Daratumumab-based regimens vs conventional clone-directed treatment in relapsed/refractory non-amyloid monoclonal immunoglobulin related kidney disease (ERA 2025) - "In the group 2 relapsed (n=1) and refractory (n=6) non-amyloid mIgKD cases were cured with other standard regimens including immunomodulatory drugs (lenalidomide, pomalidomide), melphalane, cyclophosphamide, ixazomib, elotuzumab with the median number of lines 3 (2; 3)...Other 7 refractory cases were managed with Daratumumab in combination with lenalidomide/dexamethasone (n=2), bortezomib/cyclophosphamide/dexamethasone (n=3) and as mono-agent (n=2)... Daratumumab treatment in relapse/refractory non-amyloid mIgKD does not seem to have good effects regarding HR and RR. However, further studies of larger cohorts are needed to investigate Daratumumab efficacy in severe refractory clonal disease with kidney involvement."

Amyloidosis • Hematological Malignancies • Multiple Myeloma • Nephrology • Oncology • Renal Disease

Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma. (PubMed, Front Immunol) - "Following induction chemotherapy with bortezomib, doxorubicin and dexamethasone (VAD), and subsequent consolidation therapy with ixazomib, lenalidomide, and dexamethasone, the disease progressed, manifesting as a plasmoblastic tumor in the right pelvic cavity. After two cycles of carfezomib, daratumumab, cyclophosphamide, cisplatin, etoposide and dexamethasone (KD-DECP), the patient achieved partial response...BCMA CAR-T cell accompanied with bridging radiotherapy and pomalidomide as maintenance therapy provided a promising therapy treatment for PBM, which is more aggressive and with shorter survival. Further studies are demanded to assess the efficiency and long-term benefits for this challenging subtype."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Multiple Myeloma Unpacked (ICML 2025) - P3 | "Abbreviations: DRd, daratumumab-lenalidomide-dexamethasone; DVMP, daratumumab-bortezomib-melphalan-prednisone; DVRd, daratumumab-bortezomib-lenalidomide-dexamethasone; DVTd, daratumumab-bortezomib-thalidomide-dexamethasone; IsaKRd, isatuximab-carfilzomib-lenalidomide-dexamethasone; IsaVRd, isatuximab-bortzezomib-lenalidomide-dexamethasone; KRd, carfilzomib-lenalidomide-dexamethasone; Rd, lenalidomide-dexamethasone; VMP, bortezomib-melphalan-prednisone; VRd, bortezomib-lenalidomide-dexamethasone; VTd, bortezomib-talidomide-dexamethasone...Abbreviations: Bela-Vd, belantamab mafodotin-bortezomib-dexamethasone; Cilta-cel, ciltacabtagene autoleucel; DKd, daratumumab-carfilzomib-dexamethasone; DPd, daratumumab-pomalidomide-dexamethasone; DVd, daratumumab-bortezomib-dexamethasone; Erd, elotuzumab-lenalidomide-dexamethasone; Ide-cel, idecabtagene vicleucel; IV, intravenously; Kd, carfilzomib-dexamethasone; MRD, minimal residual disease; NA, not available; ORR, overall..."

IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma • Smoldering Multiple Myeloma • B2M • CRBN • CTCs • XPO1

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant (clinicaltrials.gov) - P2 | N=42 | Active, not recruiting | Sponsor: University of Chicago | Trial completion date: Mar 2025 ➔ Mar 2027 | Trial primary completion date: Mar 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature. (PubMed, Ann Hematol) - "The oral PI ixazomib was authorized in the EU in 11/2016 and is indicated in combination with lenalidomide and dexamethasone (IRd) for the treatment of patients with relapsed/refractory MM (RRMM). With these German data, our study is closing an important gap of IRd real world data (RWD) reporting across Europe, providing median PFS/OS data and comparison to prior IRd studies. IRd is a well-tolerated and effective triplet regimen, often given as 2nd or 3rd-line therapy in RRMM, with results confirming the registration trial and other international RW-analyses."

Journal • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology

Machine learning–based sequential analysis for optimal selection between IRD and KRD regimen in multiple myeloma patients. (ASCO 2025) - "Proteasome inhibitor-based therapy, including ixazomib (IRD) or carfilzomib with lenalidomide and dexamethasone (KRD), is one of the most commonly used regimens for treatment of MM. In this study, ML models were developed to predict ETR and PFS in MM patients, facilitating personalized therapy in clinical practice. PFS models demonstrated improved performance by incorporating predicted ETR risk as an additional feature. The ETR-incorporated models with clinical and genetic data stratified patients into low-and high-risk groups proposing optimal treatment strategies to potentially improve PFS in 185 patients (35%)."

Clinical • Machine learning • Hematological Malignancies • Multiple Myeloma • Oncology

Clinical activity of novel targeting of S100A9 with tasquinimod for relapsed and refractory multiple myeloma (RRMM). (ASCO 2025) - P1 | "We previously reported preliminary results of a phase 1 trial of tasq alone and in combination with ixazomib (ixa), lenalidomide (len), and dexamethasone (dex) (IRd) in pts with RRMM (JCO 2023; 41(16)suppl:8042; NCT04405167)... In dose escalation, pts were refractory, intolerant, or contraindicated to len, pomalidomide, bortezomib, carfilzomib, and an anti-CD38 monoclonal antibody... Tasquinimod, an S100A9 inhibitor, is well tolerated in combination with IRd and has anti-myeloma activity, as evidenced by responses in patients previously refractory to Imid/PI combination therapy. Further study is warranted of tasquinimod in combination with standard myeloma therapies."

Clinical • Dyspepsia • Fatigue • Gastrointestinal Disorder • Genito-urinary Cancer • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Nephrology • Oncology • Pain • Prostate Cancer • Renal Disease • Respiratory Diseases • Solid Tumor • Thrombocytopenia • S100A9

Global Access to Multiple Myeloma Therapies. (PubMed, JCO Glob Oncol) - "Global access to novel MM therapies remains challenging, and we have identified barriers and suggested strategies to bridge this gap."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology